Osteoarthritis year 2010 in review: Pharmacological therapies

Osteoarthritis and Cartilage

Volumn 19, Issue 4, 2011, Pages 361-365

  Berenbaum, F ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Osteoarthritis; Pharmacological therapies

Indexed keywords

CELECOXIB; CHONDROITIN; DICLOFENAC; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; TANEZUMAB;

ANEMIA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; REVIEW; VISUAL ANALOG SCALE; WALKING;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; CHONDROITIN; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS; RECEPTOR, NERVE GROWTH FACTOR; UPPER GASTROINTESTINAL TRACT;

EID: 79952815595     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2011.01.019     Document Type: Review

References (9)

1. Chan F.K., Lanas A., Scheiman J., Berger M.F., Nguyen H., Goldstein J.L. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010 Jul 17, 376(9736):173-179.
2. Chan F.K., Cryer B., Goldstein J.L., Lanas A., Peura D.A., Scheiman J.M., et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010, 37(1):167-174.
3. Wandel S., Jüni P., Tendal B., Nüesch E., Villiger P.M., Welton N.J., et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010 Sep, 341:c4675.
4. Nüesch E., Trelle S., Reichenbach S., Rutjes A.W., Tschannen B., Altman D.G., et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010 Jul 16, 341:c3515.
5. Lane N.E., Schnitzer T.J., Birbara C.A., Mokhtarani M., Shelton D.L., Smith M.D., et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363(16):1521-1531.
6. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis 2010, Vol. 69. [suppl].
7. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. A phase 3 randomized, double-blind, placebo-controlled trial of analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the hip. Arthritis Rheum 2010, 62:3843.
8. Berenbaum F. Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov. Best Pract Res Clin Rheumatol 2010, 24(1):107-119.
9. Güler-Yüksel M., Allaart C.F., Watt I., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., van Schaardenburg D., et al. Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis Cartilage 2010, 18(10):1256-1262.